Assessment of tumor vascularity in lung cancer using volume perfusion CT (VPCT) with histopathologic comparison: A further step toward an individualized tumor characterization

Journal of Computer Assisted Tomography

Volumn 37, Issue 1, 2013, Pages 15-21

  Spira, Daniel ^a   Neumeister, Helge ^a   Spira, Sven Michael ^b   Hetzel, Jürgen ^a   Spengler, Werner ^a   Von Weyhern, Claus Hann ^c   Horger, Marius ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b HEC PARIS   (France)

^c UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

histopathology; k trans; lung cancer; volume perfusion CT; VPCT

Indexed keywords

BIOLOGICAL ORGANS; BLOOD; BLOOD VESSELS; COMPUTERIZED TOMOGRAPHY; DISEASES; HEMODYNAMICS;

BLOOD FLOW; BLOOD VOLUMES; CANCER SUBTYPES; HISTOPATHOLOGY; K-TRANS; LUNG CANCER; MICROVESSEL DENSITY; SMALL-CELL LUNG CANCER; VOLUME PERFUSION CT;

TUMORS;

HYPOXIA INDUCIBLE FACTOR 1; KI 67 ANTIGEN;

ADULT; AGED; ARTICLE; BLOOD VESSEL PARAMETERS; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LUNG ADENOCARCINOMA; LUNG BLOOD VOLUME; LUNG CANCER; LUNG SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MICROVESSEL DENSITY; PRIORITY JOURNAL; TUMOR BLOOD FLOW; TUMOR NECROSIS; TUMOR VASCULARIZATION; TUMOR VOLUME; VOLUME PERFUSION COMPUTER ASSISTED TOMOGRAPHY;

EID: 84872977565     PISSN: 03638715     EISSN: 15323145     Source Type: Journal    
DOI: 10.1097/RCT.0b013e318277c84f     Document Type: Article

References (34)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71-96.
2. Jenab-Wolcott J, Giantonio BJ. Bevacizumab: Current indications and future development for management of solid tumors. Expert Opin Biol Ther. 2009;9:507-517.
3. Salgia R. Prognostic significance of angiogenesis and angiogenic growth factors in nonsmall cell lung cancer. Cancer. 2011;117:3889-3899.
4. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for nonYsmall-cell lung cancer. N Engl J Med. 2006;355:2542-2550. (Pubitemid 44917502)
5. Petralia G, Preda L, D'Andrea G, et al. CT perfusion in solid-body tumours. Part I: Technical issues. Radiol Med. 2010;115:858-874.
6. Patlak CS, Blasberg RG, Fenstermacher JD. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. J Cereb Blood Flow Metab. 1983;3:1-7. (Pubitemid 13129630)
7. Miles KA. Perfusion CT for the assessment of tumour vascularity: which protocol? Br J Radiol. 2003;76:S36-S42. (Pubitemid 39530314)
8. Miles KA, Charnsangavej C, Lee FT, et al. Application of CT in the investigation of angiogenesis in oncology. Acad Radiol. 2000;7:840-850.
9. Kambadakone AR, Sahani DV. Body perfusion CT: Technique, clinical applications, and advances. Radiol Clin North Am. 2009;47:161-178.
10. Spira D, Gerlach JD, Spira SM, et al. Effect of scan time on perfusion and flow extraction product (K-trans) measurements in lung cancer using low-dose volume perfusion CT (VPCT). Acad Radiol. 2012;19:78-83.
11. Ketelsen D, Horger M, Buchgeister M, et al. Estimation of radiation exposure of 128-slice 4D-perfusion CT for the assessment of tumor vascularity. Korean J Radiol. 2010;11:547-552.
12. Kiessling F, Boese J, Corvinus C, et al. Perfusion CT in patients with advanced bronchial carcinomas: A novel chance for characterization and treatment monitoring? Eur Radiol. 2004;14:1226-1233. (Pubitemid 38979216)
13. Ulahannan SV, Brahmer Jr. Antiangiogenic agents in combination with chemotherapy in patients with advanced non-small cell lung cancer. Cancer Invest. 2011;29:325-337.
14. Giatromanolaki A, Koukourakis M, O'Byrne K, et al. Prognostic value of angiogenesis in operable non-small cell lung cancer. J Pathol. 1996;179:80-88. (Pubitemid 26180086)
15. Li WW. Tumor angiogenesis: molecular pathology, therapeutic targeting, and imaging. Acad Radiol. 2000;7:800-811.
16. Friedlander M, Brooks PC, Shaffer RW, et al. Definition of two angiogenic pathways by distinct alpha v integrins. Science. 1995;270:1500-1502. (Pubitemid 3005294)
17. Nelson AR, Fingleton B, Rothenberg ML, et al. Matrix metalloproteinases: Biologic activity and clinical implications. J Clin Oncol. 2000;18:1135-1149. (Pubitemid 30123793)
18. Hashizume H, Baluk P, Morikawa S, et al. Openings between defective endothelial cells explain tumor vessel leakiness. Am J Pathol. 2000;156:1363-1380. (Pubitemid 30660013)
19. Sudhindra A, Ochoa R, Santos ES. Biomarkers, prediction, and prognosis in nonYsmall-cell lung cancer: A platform for personalized treatment. Clin Lung Cancer. 2011;12:360-368.
20. Zakowski MF, Hussain S, Pao W, et al. Morphologic features of adenocarcinoma of the lung predictive of response to the epidermal growth factor receptor kinase inhibitors erlotinib and gefitinib. Arch Pathol Lab Med. 2009;133:470-477.
21. Tacelli N, Remy-Jardin M, Copin MC, et al. Assessment of non-small cell lung cancer perfusion: pathologic-CT correlation in 15 patients. Radiology. 2010;257:863-871.
22. Yi CA, Lee KS, Kim EA, et al. Solitary pulmonary nodules: dynamic enhanced multi-detector row CT study and comparison with vascular endothelial growth factor and microvessel density. Radiology. 2004;233:191-199. (Pubitemid 39280974)
23. Yano T, Tanikawa S, Fujie T, et al. Vascular endothelial growth factor expression and neovascularisation in non-small cell lung cancer. Eur J Cancer. 2000;36:601-609. (Pubitemid 30156845)
24. Meert AP, Feoli F, Martin B, et al. Ki67 expression in bronchial preneoplastic lesions and carcinoma in situ defined according to the new 1999 WHO/IASLC criteria: A preliminary study. Histopathology. 2004;44:47-53. (Pubitemid 38174870)
25. Cavarga I, Kocan P, Boor A, et al. Immunohistochemical markers of proliferation and vascularisation in preneoplastic bronchial lesions and invasive non-small cell lung cancer. Neoplasma. 2009;56:414-421.
26. Xiong Z, Liu JK, Hu CP, et al. Role of immature microvessels in assessing the relationship between CT perfusion characteristics and differentiation grade in lung cancer. Arch Med Res. 2010;41:611-617.
27. Vaupel P. The role of hypoxia-induced factors in tumor progression. Oncologist. 2004;9:10-17. (Pubitemid 39658341)
28. Loboda A, Jozkowicz A, Dulak J. HIF-1 and HIF-2 transcription factorsVsimilar but not identical. Mol Cells. 2010;29:435-442.
29. Mandeville HC, Ng QS, Daley FM, et al. Operable non-small cell lung cancer: Correlation of volumetric helical dynamic contrast-enhanced ct parameters with immunohistochemical markers of tumor hypoxia. Radiology. 2012;264:581-589.
30. Vaupel P, Kelleher DK, Ho?ckel M. Oxygen status of malignant tumors: pathogenesis of hypoxia and significance for tumor therapy. Semin Oncol. 2001;28:29-35. (Pubitemid 32522235)
31. Mojtahedzadeh S, Hashimoto S, Nakashima Y, et al. Clinicopathologic relevance of apoptotic and proliferative factors in human lung adenocarcinoma: Fas expression correlates with the histologic subtype, but not with the degree of apoptosis. Pathol Res Pract. 2002;198:645-654. (Pubitemid 35452872)
32. Mineo TC, Ambrogi V, Baldi A, et al. Prognostic impact of VEGF, CD31, CD34, and CD105 expression and tumour vessel invasion after radical surgery for IB-IIA non-small cell lung cancer. J Clin Pathol. 2004;57:591-597. (Pubitemid 38725758)
33. McClelland MR, Carskadon SL, Zhao L, et al. Diversity of the angiogenic phenotype in non-small cell lung cancer. Am J Respir Cell Mol Biol. 2007;36:343-350. (Pubitemid 46365285)
34. Riaz SP, Lu?chtenborg M, Coupland VH, et al. Trends in incidence of small cell lung cancer and all lung cancer. Lung Cancer. 2012;75:280-284.